Japanese firms Eisai Co. and EcoNaviSta Inc. have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan’s super-ageing society.
Taiwan-based startup Merdury Biopharmaceutical Corporation has signed a Memorandum of Understanding (MoU) with Health2Sync, Asia's largest chronic disease management platform. In this collaboration, the two parties aim to enhance the clinical evidence supporting the superior pharmacokinetic profile of oral semaglutide when delivered by Merdury's StackDose technology.
Chemomab Therapeutics has shared phase 2 results it claims show CM-101 is a triple threat in primary sclerosing cholangitis (PSC), simultaneously tackling fibrosis, inflammation and cholestasis. But the pitch fell flat with investors, who sent the biotech’s stock down around 18% when the market opened.
Just over a month after announcing its new Clinical Data Studio, Medidata has its first big customer. Eisai announced July 25 that it is incorporating Medidata’s data studio into its clinical trial management platform.
Kangfude Secures 120M RMB, Partners With Desano For Peptide Commerce Platform
Korean CDMO juggernaut Samsung Biologics continued its sales surge in the second quarter, with its biosimilars unit, Samsung Bioepis, doing much of the heavy lifting.
HOPEWELL, NEW JERSEY—A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in biologics.
Innovent has pulled off another late-phase win for its Eli Lilly-partnered GLP-1 drug candidate, linking the dual agonist to improved outcomes in type 2 diabetes to tee up a filing for approval in China.
SHANGHAI/HONG KONG, July 23 (Reuters) - Some of the biggest global drugmakers, undeterred by mounting Sino-U.S. tensions, are scouring for deals in China to replenish drug pipelines and boost their presence in the world's second-biggest pharmaceutical market, industry executives and investment bankers said.
Having had to give up on its liver disease ambitions due to a lack of funds, Hepion Pharmaceuticals has decided that its best option is to merge into Israeli biotech Pharma Two B.